Уноси

• Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. (2018-09)

  A. Spyropoulos, W. Ageno, G. Albers, C. Elliott, J. Halperin, W. Hiatt, G. Maynard, P. Steg, J. Weitz, E. Suh, T. Spiro, E. Barnathan, G. Raskob, T. Kovačević-Preradović, Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness., NEW ENGLAND JOURNAL OF MEDICINE, Vol. 379, No. 12, Sep, 2018

• CONFIRM Study Investigators - Placebo-controlled phase 3 study of oral BG-12 or glatiramer in muliple sclerosis (2012-10)

  F. RJ, M. DH, P. JT, H. M, H. E, K. M, Y. M, R. K, N. M, S. MT, V. V, D. K, S. Grgić, CONFIRM Study Investigators - Placebo-controlled phase 3 study of oral BG-12 or glatiramer in muliple sclerosis, NEW ENGLAND JOURNAL OF MEDICINE, Vol. 12, No. 367, pp. 1087 - 1097, Oct, 2012

• DEFINE Study Investigators - Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis (2012-10)

  G. R, K. L, A. DL, B. A, G. G, S. K, T. C, S. MT, Y. M, S. SI, D. KT, S. Grgić, DEFINE Study Investigators - Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis, NEW ENGLAND JOURNAL OF MEDICINE, Vol. 12, No. 367, pp. 1098 - 1107, Oct, 2012

• Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes (2020-10)

  CP. Cannon, R. Pratley, S. Dagogo-Jack, J. Mancuso, S. Huyck, U. Masiukiewicz, B. Charbonnel, R. Frederich, S. Gallo, F. Cosentino, WJ Shih, I. Gantz, SG. Terra, DZI. Cherney, DK. McGuire, V. Soldat-Stanković, Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes, NEW ENGLAND JOURNAL OF MEDICINE, Vol. 383, No. 15, pp. 1425 - 1435, Oct, 2020